Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 13/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 0.82 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.65 |
| ▸ | CDC25A | P30304 | 3/20 | 0.65 |
| ▸ | CDC25B | P30305 | 3/20 | 0.65 |
| ▸ | P4HB | P07237 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599427 | 0.90 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL15732841 | 0.89 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL15732972 | 0.87 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL358334 | 0.87 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL15732984 | 0.87 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL15732931 | 0.87 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL15732808 | 0.87 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL2599376 | 0.86 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL16884397 | 0.83 | SOAT1 (0.71) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL2599403 | 0.83 | S100A4 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | ONO PHARMACEUTICAL CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| EP-0659883-B1 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6432913-B1 | ANTIDIABETIC AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6303320-B1 | SCREENING FOR MODULATOR OF GLUCOSE USE; ADMINISTER MODULATOR TO CELLS IN VITRO, CULTURE CELLS, COMPARE PHOSPHORYLATED PROTEIN WITH GLUCOSE USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-5804411-A | KEY PROTEIN IN THE SIGNAL TRANSMISSION OF INSULIN; USEFUL IN THE PREVENTION AND/OR TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5506205-A | TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0659883-A2 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | IAPP, FAM20C, GID4 | SOAT1 1909/4885S100A4 644/4885MAP2K7 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.